Madrigal Pharmaceuticals (MDGL) to Release Quarterly Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($4.32) per share and revenue of $98.53 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Madrigal Pharmaceuticals Stock Down 4.2 %

Madrigal Pharmaceuticals stock traded down $14.80 during midday trading on Friday, hitting $336.23. The stock had a trading volume of 256,941 shares, compared to its average volume of 415,641. The stock has a market cap of $7.33 billion, a P/E ratio of -13.41 and a beta of -0.38. The business has a fifty day moving average price of $319.24 and a 200 day moving average price of $281.14. Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $368.29. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. JMP Securities reaffirmed a "market outperform" rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. B. Riley upped their target price on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. HC Wainwright upped their target price on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a report on Tuesday, January 14th. Finally, UBS Group upped their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a "buy" rating in a report on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $351.67.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, insider Carole Huntsman sold 347 shares of the company's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the completion of the sale, the insider now directly owns 10,438 shares in the company, valued at $3,499,235.12. This represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert E. Waltermire sold 103 shares of the company's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $34,529.72. Following the completion of the sale, the vice president now owns 4,955 shares of the company's stock, valued at $1,661,114.20. This trade represents a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,090 shares of company stock worth $3,883,621 over the last ninety days. Company insiders own 22.80% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.